<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Detection rates for recurrent prostate cancer in men with a rising PSA after locoregional therapy using prostate-specific radiolabeled tracers for PET, as a function of the PSA level</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Detection rates for recurrent prostate cancer in men with a rising PSA after locoregional therapy using prostate-specific radiolabeled tracers for PET, as a function of the PSA level</h1>
<div class="graphic"><div class="figure"><div class="ttl">Detection rates for recurrent prostate cancer in men with a rising PSA after locoregional therapy using prostate-specific radiolabeled tracers for PET, as a function of the PSA level</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16.6%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Study</td> <td class="subtitle1" rowspan="2">PET radiotracer</td> <td class="subtitle1" rowspan="2">Percent of patients with BCR</td> <td class="subtitle1" colspan="3">Percent of patients with positive PET/CT</td> </tr> <tr> <td class="subtitle2">PSA &lt;1.0</td> <td class="subtitle2">PSA 1.0 to 2.0</td> <td class="subtitle2">PSA &gt;2.0</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Choline</td> </tr> <tr> <td class="indent1">Mitchell<sup>[1]</sup></td> <td>C-11 Choline</td> <td>100% (176 of 176)</td> <td>44% (15 of 34)</td> <td>67% (21 of 31)</td> <td>86% (96 of 111)</td> </tr> <tr> <td class="indent1">Giovacchini<sup>[2]</sup></td> <td>C-11 Choline</td> <td>100% (358 of 358)</td> <td>19% (27 of 141)</td> <td>46% (39 of 85)</td> <td>72% (95 of 132)</td> </tr> <tr> <td class="indent1">Richter<sup>[3]</sup></td> <td>C-11 Choline</td> <td>100% (73 of 73)</td> <td>7% (1 of 15)</td> <td>46% (6 of 13)</td> <td>80% (36 of 45)</td> </tr> <tr> <td class="indent1">Krause<sup>[4]</sup></td> <td>C-11 Choline</td> <td>100% (63 of 63)</td> <td>36% (8 of 22)</td> <td>43% (3 of 7)</td> <td>71% (24 of 34)</td> </tr> <tr> <td class="indent1">Castellucci<sup>[5]</sup></td> <td>C-11 Choline</td> <td>100% (190 of 190)</td> <td>19% (10 of 51)</td> <td>25% (10 of 39)</td> <td>54% (54 of 100)</td> </tr> <tr> <td class="indent1">Nanni<sup>[6]</sup></td> <td>C-11 Choline</td> <td>100% (89 of 89)</td> <td>14% (4 of 28)</td> <td>29% (8 of 28)</td> <td>55% (18 of 33)</td> </tr> <tr> <td class="indent1">Schwenck<sup>[7]</sup></td> <td>C-11 Choline</td> <td>100% (101 of 101)</td> <td>44% (8 of 18)</td> <td>81% (21 of 26)</td> <td>89% (51 of 57)</td> </tr> <tr> <td class="indent1">Cimitan<sup>[8]</sup></td> <td>F-18 Choline</td> <td>100% (1000 of 1000)</td> <td>31% (66 of 211)</td> <td>43% (66 of 153)</td> <td>81% (513 of 636)</td> </tr> <tr> <td class="indent1">Schillaci<sup>[9]</sup></td> <td>F-18 Choline</td> <td>100% (49 of 49)</td> <td>20% (2 of 10)</td> <td>56% (5 of 9)</td> <td>83% (25 of 30)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Morigi<sup>[10]</sup></td> <td>F-18 Methchol</td> <td>100% (38 of 38)</td> <td>13% (2 of 16)</td> <td>36% (5 of 14)</td> <td>63% (5 of 8)</td> </tr> <tr> <td class="subtitle2_left" colspan="6">PSMA</td> </tr> <tr> <td class="indent1">Schwenck<sup>[7]</sup></td> <td>Ga-68 PSMA</td> <td>100% (101 of 101)</td> <td>61% (11 of 18)</td> <td>76% (20 of 26)</td> <td>93% (53 of 57)</td> </tr> <tr> <td class="indent1">Morigi<sup>[10]</sup></td> <td>Ga-68 PSMA</td> <td>100% (38 of 38)</td> <td>50% (8 of 16)</td> <td>71% (10 of 14)</td> <td>88% (7 of 8)</td> </tr> <tr> <td class="indent1">Afshar-Oromieh<sup>[11]</sup></td> <td>Ga-68 PSMA</td> <td>100% (319 of 319)</td> <td>53% (27 of 51)</td> <td>72% (28 of 39)</td> <td>92% (204 of 221)</td> </tr> <tr> <td class="indent1">Eiber<sup>[12]</sup></td> <td>Ga-68 PSMA</td> <td>100% (248 of 248)</td> <td>67% (35 of 52)</td> <td>93% (67 of 72)</td> <td>97% (120 of 124)</td> </tr> <tr> <td class="indent1">Bluemel<sup>[13]</sup></td> <td>Ga-68 PSMA</td> <td>100% (32 of 32)</td> <td>29% (4 of 14)</td> <td>46% (5 of 11)</td> <td>71% (5 of 7)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Verburg<sup>[14]</sup></td> <td>Ga-68 PSMA</td> <td>100% (155 of 155)</td> <td>44% (12 of 27)</td> <td>79% (15 of 19)</td> <td>89% (97 of 109)</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Fluciclovine</td> </tr> <tr> <td class="indent1">Nanni<sup>[6]</sup></td> <td>F-18 FACBC</td> <td>100% (89 of 89)</td> <td>21% (6 of 28)</td> <td>46% (13 of 28)</td> <td>55% (18 of 33)</td> </tr> <tr> <td class="indent1">Odewole<sup>[15]</sup></td> <td>F-18 FACBC</td> <td>100% (53 of 53)</td> <td>38% (3 of 8)</td> <td>78% (7 of 9)</td> <td>86% (31 of 36)</td> </tr> <tr> <td class="indent1">Bach-Gansmo<sup>[16]</sup></td> <td>F-18 FACBC</td> <td>100% (596 of 596)</td> <td>41% (53 of 128)</td> <td>58% (N?)</td> <td>75 to 85% (N?)</td> </tr> <tr> <td class="indent1">Schuster<sup>[17]</sup></td> <td>F-18 FACBC</td> <td>100% (93 of 93)</td> <td> </td> <td>72% (N?)</td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes">PSA: prostate-specific antigen; PET: positron emission tomography; BCR: biochemical recurrence; CT: computed tomography; PSMA: prostate-specific membrane antigen.</div><div class="graphic_reference">References:

<ol>
<li>Mitchell CR, Lowe VJ, Rangel LJ, et al. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol 2013; 189:1308.</li>
<li>Giovacchini G, Picchio M, Coradeschi, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37:301.</li>
<li>Richter JA, Rodriguez M, Rioja J, et al. Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010; 12:210.</li>
<li>Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:18.</li>
<li>Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009; 50:1394.</li>
<li>Nanni C, Zanoni L, Pultrone C, et al. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: Results of a prospective trial. Eur J Nucl Med Mol Imaging 2016; 43:1601.</li>
<li>Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging 2017; 44:92.</li>
<li>Cimitan M, Evangelista L, Hodolic M, et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: Experience with 1,000 patients. J Nucl Med 2015; 56:209.</li>
<li>Schillaci O, Calabria F, Tabolozza M, et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39:589.</li>
<li>Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med 2015:561185.</li>
<li>Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42:197.</li>
<li>Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56:668.</li>
<li>Bluemel C, Krebs M, Polat B, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med 2016; 41:515.</li>
<li>Verburg FA, Pfister D, Heidenreich A, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43:397.</li>
<li>Odewole OA, Tade FI, Nieh PT, et al. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: Comparison with CT. Eur J Nucl Med Mol Imaging 2016; 43:1773.</li>
<li>Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography/computerized tomography imaging in the staging of biochemically recurrent prostate cancer. J Urol 2017; 197(3 Pt 1):676.</li>
<li>Schuster DM, Nieh PT, Jani AB, et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: Results of a prospective clinical trial. J Urol 2014; 191:1446.</li>
</ol>

Reproduced from: Evans JD, Jethwa KR, Ost P, et al. Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiat Oncol 2018; 8:28. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 118753 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
